Navigation Links
Caliper Life Sciences' Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
Date:4/28/2008

- IVIS Imaging System Provides Real-Time Insight on Viability of Infectious

Disease Treatment Options -

HOPKINTON, Mass., April 28 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced that the Texas A&M Health Science Center Research Foundation (HSCRF) is using the IVIS Spectrum imaging system to speed the development of more effective therapeutic treatments for tuberculosis. Research efforts and the purchase of the IVIS system are funded through a grant to the Texas A&M Health Science Center from the Bill & Melinda Gates Foundation.

Tuberculosis currently affects nearly one-third of the world's population and remains a global threat due to severe and drug-resistant strains. According to the World Health Organization, tuberculosis is one of the most serious infectious diseases in the world. Caliper is dedicated to assisting the global fight against infectious diseases and aiding the discovery of life-saving treatments.

Researchers at the Texas A&M Health Science Center College of Medicine and a consortium of leading tuberculosis researchers at Washington University and Stanford University School of Medicine are actively studying tuberculosis infections in live animals using in vivo imaging technology. Caliper's IVIS Spectrum was specifically chosen for its highly sensitive luminescence detection and ability to successfully image, track and quantify tuberculosis infections using fluorescence. The IVIS system enables researchers to visualize the progression of the disease and impact of therapeutic candidates in real time. This rapid evaluation of in vivo efficacy allows researchers to quickly adapt efforts and progress towards effective treatments for the disease.

"We are quite optimistic that this research collaboration will uncover new and promising discoveries in the fight against tuberculosis," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Caliper's imaging technology has proven to be integral in other discovery efforts for finding new ways and treatments to combat infectious disease. This is a great opportunity to exploit Caliper's imaging technology to make a major impact in this world."

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper and IVIS are registered trademarks, and Spectrum is a trademark, of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , one of this ... A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the round was intended ...
(Date:2/11/2016)... CARLSBAD, Calif. , Feb.11, 2016  Ionis Pharmaceuticals, Inc. ... a live webcast on Thursday, February 25 at 11:30 a.m. ... on pipeline and business progress. www.ionispharma.com . ... at the same address. --> www.ionispharma.com . A ... the same address. --> Interested parties may listen ...
(Date:2/11/2016)... -- Indiso ltd , a medical technology company ... respiratory diseases announced today positive results in its clinical ... patients show improvements in respiratory functions and other clinical ... Upper and lower respiratory tract diseases and allergy ... reached epidemic level. Increasing number of studies however show ...
Breaking Medicine Technology:
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... ... an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for ... not-for-profit Catholic health care system that’s partnering with Intel on value-based health benefits ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical Systems, ... with highly adaptable algorithms, has been updated to help Emergency Department physicians and ... consistent with Zikas and a travel history to affected regions, or potential exposure ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... call for nominations seeking candidates for the Board of Commissioners. Individuals interested in ... skills and experience with diversity of clinical practice settings and across allied health ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you back from ... poses a question as a challenge for his readers to examine the full ... Being" (published by Partridge Singapore), Clarke explores the subject with more depth, revealing ...
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
Breaking Medicine News(10 mins):